Create Excellence in Pharmaceuticals，Enhance Innovation in China
Founded in 1995, Hansoh Pharma is a leading innovation-driven pharmaceutical company in China. Upholding the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", we are committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes. The Company has been ranked top 30 among China's Top 100 Companies in Pharmaceutical Industry and top 3 among China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for consecutive years, and is a national key high-tech enterprise and national technology innovation demonstration enterprise. The Company went listed on the Stock Exchange of Hong Kong Ltd. in June 2019 (HK.03692).
We have excellent R&D capabilities and over 20 years of R&D experience. The Company has established R&D centers in Maryland, the U.S., and Shanghai, Lianyungang，Changzhou of China, created a R&D system that covers the whole process from cutting-edge information collection, compound design and screening, pharmacological and toxicological research to pilot scale-up, and established a number of national R&D institutions including National Enterprise Technology Center, Postdoctoral Research Station, and National and Local Joint Engineering Center for Long-acting Polypeptide Drugs. We have made great efforts to grow and engage high-level technical talents. Up to December 2020, with the support from more than 1,600 professional R&D personnel, we have undertaken more than 50 national scientific research projects including 863 Program, "Major New Drug Innovation" Technology Program, and Torch Program; have won two second prizes in the National Scientific and Technological Progress Award and one gold medal in China Patent Award; have been granted more than 300 invention patents at home and abroad; and have participated in the formulation of nearly 150 national standards.
After more than 20 years of continuous investment in R&D, we have so far five Class 1 innovative drugs in the market, more than 100 drugs in development, and more than 20 innovative drugs in the clinical stage, forming a rich pipeline.
We remain dynamically aligned with the global advanced access level by continuously designing and building production facilities and lines in accordance with international advanced standards and using advanced production equipment. Our production quality system has been officially certified by FDA of the United States, EMA of the European Union and PMDA of Japan, and our finished preparations and APIs have been approved for marketing in Europe, America, Japan, etc.
In the future, upholding the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", we will accelerate the pace of technological innovation, continue our dedication to meeting unmet clinical needs, and keep developing more innovative drugs to improve the health and life quality of human beings.
